• Company
    • Overview
    • Leadership
    • Company History
    • CSR
    • Diversity
    • JSR LS
  • Newsroom
    • Latest News
    • Archives
    • In the News
    • Calendar
    • Press Kit
    • Media Inquiries
    • Xpressions Blog
  • Careers
    • Overview
    • Open Positions
    • GPTW
    • Submit Resume
  • Contact
    • General Inquiries
SELEXIS-logo-with-tagline-2016MAR19-V600-Full-Color
Selexis Logo Web
  • Capabilities
    • Overview
    • Cell Line Development
  • Technologies
    • Overview
    • Gene Technology
    • CHO-M Cell Line
  • Solutions
    • Overview
    • Bispecifics
    • Difficult-to-Express Proteins
    • Gene to GMP
    • Monoclonal Antibodies
  • Pipeline
    • Overview
    • Partners
    • Protein formats
  • Knowledge Center
    • TECHNOLOGY FAQS
    • SCIENTIFIC PUBLICATIONS
    • SCIENTIFIC POSTERS
    • WHITE PAPERS AND ARTICLES
    • VIDEOS
    • FACT SHEETS
    • WEBINARS
  • Company
    • Overview
    • Leadership
    • Company History
    • CSR
    • Diversity
    • JSR LS
  • Newsroom
    • Latest News
    • Archives
    • In the News
    • Calendar
    • Press Kit
    • Media Inquiries
    • Xpressions Blog
  • Careers
    • Overview
    • Open Positions
    • GPTW
    • Submit Resume
  • Contact
    • General Inquires

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

  • OVERVIEW
  • TECHNOLOGY FAQS
  • TECHNOLOGY SHEETS
  • SCIENTIFIC PUBLICATIONS
  • SCIENTIFIC POSTERS
  • WHITE PAPERS AND ARTICLES
  • VIDEOS
  • FACT SHEETS

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

Capabilities

  • Overview
  • CLD
  • Clonality

Technologies

  • Overview
  • Gene Technology
  • CHO Cell Line

Solutions

  • Overview
  • Bispecifics
  • Difficult-to Express-Proteins
  • Gene to GMP

Pipeline

  • Overview
  • Testimonials
  • Partners

Knowledge Center

  • Latest News
  • Archives
  • In the News
  • Calendar
  • Press Kit
  • Media Inquiries
  • Xpressions Blog
Selexis CHO Cells in Suspension-1

Press Kit

 

Corporate Logos


 

Selexis Logo Web
 
Selexis Logo (png)
SELEXIS logo with tagline 2016MAR19 V1200-Full Color
 
Selexis Logo with Tagline (png)
JSRLogo-gray
 
A JSR Life Sciences Company Logo (png)

Videos and Photos


 

Fact Sheets and Backgrounders


 

SELEXIS Corporate Overview Letter 2022OCT07 V10 FD Thumbnail-1
 
Corporate Overview 
SELEXIS Capabilities Letter 2022OCT11 V10 FD Thumbnail
 
Capabilities
SELEXIS Rescue Promising Programs Letter thumbnail
 
Rescue Promising Programs




Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.

From ubiquitous immunoglobulin-based drugs such as monoclonal and bispecific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™


Selexis Monoclonal Antibodies block

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.

Learn More
Selexis Difficult-to-Express Proteins block

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis Bispecific Antibodies block

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More
  • Capabilities
  • Technologies
  • Solutions
  • Pipeline
  • Knowledge Center
  • Company
  • Newsroom
  • Careers
  • Contact
Selexis SA footer Logo

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

A JSR Life Sciences Company Logo
EN-BEST MEDIUM WORKPLACES_CMYK

Latest News

October 31, 2022

KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer

Read More
September 8, 2022

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Read More
  • Terms of Use
  • Privacy
  • Cookies
  • Social Media

Copyright© 2023 Selexis SA. All Rights Reserved.